The PIRAMID program participated in the first edition of Brain & Breakfast organized by the Sciences Campus of the University of Nantes, which aims to disseminate scientific culture to the general public.

For this first session, researchers from the PIRAMID program, among them Agnès Quéméner from the Mocka Lab, took you to the heart of the protein-protein interaction to design new molecules capable of strengthening or preventing an interaction and thus act against certain pathologies such as cancer, cardiovascular diseases and fungal infections …

Tuesday, January 29, 2019, from 9:30 am to 10:30 am at the Cafet ‘Sciences in Bâtiment 1 of the Lombarderie Campus.

New publication from the Mocka Lab! « Emergence of NK Cell Hyporesponsiveness after Two IL-15 Stimulation Cycles » by  Marie Frutoso et al., published in the  Journal of Immunology.

see « Publications » section

SOTIO to Present Translational Data of the IL-15 Superagonist SO-C101 at 2018 AACR Annual Meeting

SOTIO, a biotechnology company owned by the PPF Group, announces today presentation of a poster on SO-C101 at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2018. The poster, titled “Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response,” will highlight preclinical and translational data evaluating SO-C101 (RLI-15). The AACR Annual Meeting will be held on April 14 – 18, 2018 in Chicago, Illinois.

April 10, 2018
Source: Press Release, Prague

PPF Group acquires a minority stake in biotech company Cytune Pharma in cooperation with SOTIO.

PPF Group has acquired a significant minority stake in Cytune Pharma SAS, a French biotechnology company focused on researching and developing new therapies for immune modulation aimed at enhancing immune response of patients suffering from cancer and infectious diseases. Cytune’s platform based on modified IL-15 offers the possibility of combinations with other immunotherapeutic strategies, including checkpoint inhibitors.